April 12 (Bloomberg) -- Merck & Co.'s experimental arthritis drug Arcoxia shouldn’t be allowed on the U.S. market, an advisory panel said, citing some of the same risks that led to the withdrawal of the previous treatment Vioxx.
April 12 (Bloomberg) -- Merck & Co.'s experimental arthritis drug Arcoxia shouldn’t be allowed on the U.S. market, an advisory panel said, citing some of the same risks that led to the withdrawal of the previous treatment Vioxx.
